序言及說明
攝護腺癌專家介紹(依姓氏筆畫順序)
2015 年 10 月 2 日臺灣攝護腺癌專家共識會議參與名單及第二輪通訊投票名單
目錄 15
中英文專有名詞對照 ...
議題一 ...
Management of men with castration-naïve metastatic prostate cancer 評論分析:吳東霖
議題二 ...
Definition of castration resistance 評論分析:吳東霖
議題三 ...
Management of men with non-metastatic (M0) CRPC 評論分析:吳東霖
議題四 ...
Value of endocrine manipulations without proven survival benefit in men with metastatic CRPC
評論分析:吳東霖
議題五 ...
Treatment choice and sequencing for men with metastatic CRPC 評論分析:張延驊
1 3 13
17 19
29
35
43
47
議題六 ...
Staging and monitoring of treatment 評論分析:張延驊
議題七 ...
Use of osteoclast-targeted agents for reducing risk of SREs and SSEs in men with CRPC
評論分析:蒲永孝
議題八 ...
Predictive markers and clinically important factors for decision making in daily clinical practice
評論分析:蒲永孝
議題九 ...
Tumor biopsy 評論分析:蒲永孝
議題十 ...
Oligometastatic castration-naïve prostate cancer 評論分析:蒲永孝
議題十一 ...
Multidisciplinary care of men with prostate cancer 評論分析:蒲永孝
67
89
97
107
113
119
15 16
序言及說明
攝護腺癌專家介紹(依姓氏筆畫順序)
2015 年 10 月 2 日臺灣攝護腺癌專家共識會議參與名單及第二輪通訊投票名單
目錄 15
中英文專有名詞對照 ...
議題一 ...
Management of men with castration-naïve metastatic prostate cancer 評論分析:吳東霖
議題二 ...
Definition of castration resistance 評論分析:吳東霖
議題三 ...
Management of men with non-metastatic (M0) CRPC 評論分析:吳東霖
議題四 ...
Value of endocrine manipulations without proven survival benefit in men with metastatic CRPC
評論分析:吳東霖
議題五 ...
Treatment choice and sequencing for men with metastatic CRPC 評論分析:張延驊
1 3 13
17 19
29
35
43
47
議題六 ...
Staging and monitoring of treatment 評論分析:張延驊
議題七 ...
Use of osteoclast-targeted agents for reducing risk of SREs and SSEs in men with CRPC
評論分析:蒲永孝
議題八 ...
Predictive markers and clinically important factors for decision making in daily clinical practice
評論分析:蒲永孝
議題九 ...
Tumor biopsy 評論分析:蒲永孝
議題十 ...
Oligometastatic castration-naïve prostate cancer 評論分析:蒲永孝
議題十一 ...
Multidisciplinary care of men with prostate cancer 評論分析:蒲永孝
67
89
97
107
113
119
15 16